Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBT Margin: 2013-2025

Historic EBT Margin for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -384.73%.

  • Coherus Oncology's EBT Margin rose 40177.00% to -384.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 21.98%, marking a year-over-year increase of 24900.00%. This contributed to the annual value of 10.68% for FY2024, which is 10330.00% up from last year.
  • Per Coherus Oncology's latest filing, its EBT Margin stood at -384.73% for Q3 2025, which was up 12.06% from -437.51% recorded in Q2 2025.
  • Coherus Oncology's EBT Margin's 5-year high stood at 79.66% during Q4 2024, with a 5-year trough of -2,947.83% in Q1 2024.
  • For the 3-year period, Coherus Oncology's EBT Margin averaged around -552.78%, with its median value being -384.73% (2025).
  • Its EBT Margin has fluctuated over the past 5 years, first slumped by 271,436bps in 2024, then surged by 232,409bps in 2025.
  • Coherus Oncology's EBT Margin (Quarterly) stood at -62.34% in 2021, then slumped by 6,747bps to -129.81% in 2022, then skyrocketed by 4,278bps to -87.03% in 2023, then skyrocketed by 16,669bps to 79.66% in 2024, then surged by 40,177bps to -384.73% in 2025.
  • Its last three reported values are -384.73% in Q3 2025, -437.51% for Q2 2025, and -623.74% during Q1 2025.